vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $50.3M, roughly 1.7× READING INTERNATIONAL INC). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -38.1%, a 33.0% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -14.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 5.6%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.

PRCT vs RDI — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.7× larger
PRCT
$83.1M
$50.3M
RDI
Growing faster (revenue YoY)
PRCT
PRCT
+34.4% gap
PRCT
20.2%
-14.2%
RDI
Higher net margin
RDI
RDI
33.0% more per $
RDI
-5.1%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
5.6%
RDI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCT
PRCT
RDI
RDI
Revenue
$83.1M
$50.3M
Net Profit
$-31.6M
$-2.6M
Gross Margin
64.9%
Operating Margin
-4.1%
-1.9%
Net Margin
-38.1%
-5.1%
Revenue YoY
20.2%
-14.2%
Net Profit YoY
-27.9%
-14.5%
EPS (diluted)
$-0.56
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
RDI
RDI
Q1 26
$83.1M
Q4 25
$76.4M
$50.3M
Q3 25
$83.3M
$52.2M
Q2 25
$79.2M
$60.4M
Q1 25
$69.2M
$40.2M
Q4 24
$68.2M
$58.6M
Q3 24
$58.4M
$60.1M
Q2 24
$53.4M
$46.8M
Net Profit
PRCT
PRCT
RDI
RDI
Q1 26
$-31.6M
Q4 25
$-29.8M
$-2.6M
Q3 25
$-21.4M
$-4.2M
Q2 25
$-19.6M
$-2.7M
Q1 25
$-24.7M
$-4.8M
Q4 24
$-18.9M
$-2.2M
Q3 24
$-21.0M
$-7.0M
Q2 24
$-25.6M
$-12.8M
Gross Margin
PRCT
PRCT
RDI
RDI
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
RDI
RDI
Q1 26
-4.1%
Q4 25
-40.6%
-1.9%
Q3 25
-27.8%
-0.6%
Q2 25
-28.0%
4.8%
Q1 25
-39.7%
-17.2%
Q4 24
-28.9%
2.6%
Q3 24
-38.4%
-0.6%
Q2 24
-50.3%
-16.4%
Net Margin
PRCT
PRCT
RDI
RDI
Q1 26
-38.1%
Q4 25
-39.1%
-5.1%
Q3 25
-25.7%
-8.0%
Q2 25
-24.7%
-4.4%
Q1 25
-35.8%
-11.8%
Q4 24
-27.6%
-3.8%
Q3 24
-35.9%
-11.7%
Q2 24
-48.0%
-27.4%
EPS (diluted)
PRCT
PRCT
RDI
RDI
Q1 26
$-0.56
Q4 25
$-0.54
$-0.11
Q3 25
$-0.38
$-0.18
Q2 25
$-0.35
$-0.12
Q1 25
$-0.45
$-0.21
Q4 24
$-0.34
$-0.11
Q3 24
$-0.40
$-0.31
Q2 24
$-0.50
$-0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
RDI
RDI
Cash + ST InvestmentsLiquidity on hand
$245.6M
$10.5M
Total DebtLower is stronger
$51.7M
$185.1M
Stockholders' EquityBook value
$347.7M
$-18.2M
Total Assets
$487.1M
$434.9M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
RDI
RDI
Q1 26
$245.6M
Q4 25
$286.5M
$10.5M
Q3 25
$294.3M
$8.1M
Q2 25
$302.7M
$9.1M
Q1 25
$316.2M
$5.9M
Q4 24
$333.7M
$12.4M
Q3 24
$196.8M
$10.1M
Q2 24
$214.1M
$9.3M
Total Debt
PRCT
PRCT
RDI
RDI
Q1 26
$51.7M
Q4 25
$51.6M
$185.1M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
$202.7M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
RDI
RDI
Q1 26
$347.7M
Q4 25
$365.9M
$-18.2M
Q3 25
$380.3M
$-12.1M
Q2 25
$385.8M
$-7.7M
Q1 25
$389.2M
$-8.1M
Q4 24
$402.2M
$-4.4M
Q3 24
$241.2M
$1.6M
Q2 24
$251.8M
$6.5M
Total Assets
PRCT
PRCT
RDI
RDI
Q1 26
$487.1M
Q4 25
$508.1M
$434.9M
Q3 25
$511.5M
$435.2M
Q2 25
$513.1M
$438.1M
Q1 25
$519.4M
$441.0M
Q4 24
$534.0M
$471.0M
Q3 24
$374.1M
$495.7M
Q2 24
$374.4M
$494.9M
Debt / Equity
PRCT
PRCT
RDI
RDI
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
RDI
RDI
Operating Cash FlowLast quarter
$4.3M
Free Cash FlowOCF − Capex
$4.1M
FCF MarginFCF / Revenue
8.2%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
RDI
RDI
Q1 26
Q4 25
$-10.3M
$4.3M
Q3 25
$-6.6M
$295.0K
Q2 25
$-15.0M
$1.6M
Q1 25
$-17.0M
$-7.7M
Q4 24
$-32.4M
$8.0M
Q3 24
$-18.8M
$1.3M
Q2 24
$-15.7M
$-10.4M
Free Cash Flow
PRCT
PRCT
RDI
RDI
Q1 26
Q4 25
$-12.2M
$4.1M
Q3 25
$-9.5M
$-246.0K
Q2 25
$-17.8M
$1.2M
Q1 25
$-18.8M
$-8.0M
Q4 24
$-33.6M
$7.0M
Q3 24
$-19.0M
$-1.1M
Q2 24
$-16.8M
$-10.6M
FCF Margin
PRCT
PRCT
RDI
RDI
Q1 26
Q4 25
-15.9%
8.2%
Q3 25
-11.4%
-0.5%
Q2 25
-22.5%
1.9%
Q1 25
-27.2%
-19.8%
Q4 24
-49.2%
12.0%
Q3 24
-32.6%
-1.8%
Q2 24
-31.4%
-22.7%
Capex Intensity
PRCT
PRCT
RDI
RDI
Q1 26
Q4 25
2.4%
0.3%
Q3 25
3.4%
1.0%
Q2 25
3.5%
0.6%
Q1 25
2.7%
0.6%
Q4 24
1.7%
1.7%
Q3 24
0.4%
4.0%
Q2 24
2.0%
0.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

RDI
RDI

Cinema Exhibition Segment$46.9M93%
Real Estate Revenue$3.4M7%

Related Comparisons